苯茚胺 | 82-88-2

• 物质功能分类: 原料药 - 抗变态反应药 - 抗组胺药
• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 中文名称: 苯茚胺
• 英文名称: phenindamine
• 英文别名: 2-methyl-9-phenyl-2,3,4,9-tetrahydro-1H-indeno[2,1-c]pyridine；2-Methyl-9-phenyl-2,3,4,9-tetrahydro-1H-indeno[2,1-c]pyridin；Phenindamin；2-methyl-9-phenyl-1,3,4,9-tetrahydroindeno[2,1-c]pyridine
• CAS: 82-88-2
• 化学式: C₁₉H₁₉N
• 分子量: 261.367
• InChiKey: ISFHAYSTHMVOJR-UHFFFAOYSA-N

物化性质

• 熔点：
  90-91°
• 密度：
  1.17
• 物理描述：
  Solid
• 溶解度：
  2.77e-02 g/L
• 保留指数：
  2109;2180;2158;2147;2167

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

ADMET

毒理性

• 毒性总结

抗组胺药如苯印胺似乎与组胺竞争效应细胞上的组胺H1-受体位点。抗组胺药拮抗通过激活H1-受体位点介导的组胺的药理作用，从而减少过敏反应和涉及组胺释放的组织损伤反应的强度。

Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release.

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 致癌物分类

对人类无致癌性（未列入国际癌症研究机构IARC清单）。

No indication of carcinogenicity to humans (not listed by IARC).

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用总结：偶尔小剂量的非那根不会对哺乳婴儿产生不良影响。较大剂量或更长时间的使用可能会导致婴儿出现嗜睡和其他反应，或者减少奶量，特别是在与伪麻黄碱等拟交感神经药联合使用或在母乳喂养尚未建立时。首选非嗜睡性抗组胺药作为替代。 ◉ 对哺乳婴儿的影响：没有报告在母亲使用非那根治疗期间哺乳的婴儿。在一项电话随访研究中，母亲报告有10%的婴儿接触到各种抗组胺药后出现烦躁和肠绞痛症状，1.6%的婴儿出现嗜睡。所有反应均未需要医疗关注，且没有患者使用非那根。 ◉ 对泌乳和母乳的影响：在非哺乳期妇女和产后早期妇女中，通过注射给予相对高剂量的抗组胺药可以降低基础血清催乳素水平。然而，产后母亲在接受抗组胺药预处理后，吸吮诱导的催乳素分泌并未受到影响。尚未研究较低口服剂量的抗组胺药是否对血清催乳素有相同的影响，或者催乳素的影响是否对母乳喂养成功有任何后果。对于已经建立泌乳的母亲，催乳素水平可能不会影响她的哺乳能力。

◉ Summary of Use during Lactation:Small occasional doses of phenindamine would not be expected to cause any adverse effects in breastfed infants. Larger doses or more prolonged use may cause drowsiness and other effects in the infant or decrease the milk supply, particularly in combination with a sympathomimetic such as pseudoephedrine or before lactation is well established. The nonsedating antihistamines are preferred alternatives. ◉ Effects in Breastfed Infants:There are no reports of infants breastfed during maternal therapy with phenindamine. In one telephone follow-up study, mothers reported irritability and colicky symptoms 10% of infants exposed to various antihistamines and drowsiness was reported in 1.6% of infants. None of the reactions required medical attention and none of the patients were taking phenindamine. ◉ Effects on Lactation and Breastmilk:Antihistamines in relatively high doses given by injection can decrease basal serum prolactin in nonlactating women and in early postpartum women. However, suckling-induced prolactin secretion is not affected by antihistamine pretreatment of postpartum mothers. Whether lower oral doses of antihistamines have the same effect on serum prolactin or whether the effects on prolactin have any consequences on breastfeeding success have not been studied. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

来源:Drugs and Lactation Database (LactMed)

毒理性

• 症状

苯印胺过量的症状包括极度嗜睡、混乱、虚弱、耳鸣、视力模糊、瞳孔扩大、口干、脸红、发热、颤抖、失眠、幻觉，以及可能的癫痫发作。

Symptoms of a phenindamine overdose include extreme sleepiness, confusion, weakness, ringing in the ears, blurred vision, large pupils, dry mouth, flushing, fever, shaking, insomnia, hallucinations, and possibly seizures.

来源:Toxin and Toxin Target Database (T3DB)

反应信息

• 作为反应物：
  描述：

  硫酸 、 苯茚胺 、 alkaline earth salt of/the/ methylsulfuric acid 生成 2-methyl-9-phenyl-1,2,3,4-tetrahydro-9H-indeno[2,1-c]pyridine-4a,9a-diol
  参考文献：
  名称：

  PYRIDINDENE DERIVATIVES. II. THE CHEMISTRY OF 2-METHYL-9-PHENYL-2,3,4,9-TETRAHYDRO-1-PYRIDINDENE

  摘要：

  DOI：

  10.1021/jo01127a021
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 sodium hydroxide 、 氯化亚砜 作用下， 生成 苯茚胺
  参考文献：
  名称：

  Pyridindenes and process for their manufacture

  摘要：

  公开号：

  US02546652A1

文献信息

• SUBSTITUTED INDOLES
  申请人：Gant Thomas G.

  公开号：US20090191183A1

  公开（公告）日：2009-07-30

  Disclosed herein are substituted indole cysteinyl leukotriene receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

  本文揭示了Formula I的替代吲哚半胱氨酸白三烯受体调节剂，其制备方法，药物组合物以及使用方法。
• [EN] TRICYCLIC TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY<br/>[FR] COMPOSÉS TRIAZOLES TRICYCLIQUES MODULANT L'ACTIVITÉ HSP90
  申请人：SYNTA PHARMACEUTICALS CORP

  公开号：WO2009139916A1

  公开（公告）日：2009-11-19

  The present invention relates to substituted tricyclic triazole compounds and compositions comprising substituted tricyclic triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a compound of the invention, or a composition comprising such a compound.

  本发明涉及替代三环三唑化合物和包含替代三环三唑化合物的组合物。该发明还涉及在需要的受体中抑制Hsp90活性的方法，以及预防或治疗高增殖性疾病（如癌症）的方法，其中包括向受体施用本发明的化合物或包含这种化合物的组合物。
• [EN] SPIROLACTAM CGRP RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE RÉCEPTEUR DE CGRP À BASE DE SPIROLACTAME
  申请人：MERCK SHARP & DOHME

  公开号：WO2013169567A1

  公开（公告）日：2013-11-14

  The present invention is directed to spirolactam analogues which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及螺内酰胺类似物，其为CGRP受体拮抗剂，可用于治疗或预防涉及CGRP的疾病，如偏头痛。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗涉及CGRP的这类疾病中使用这些化合物和组合物。
• [EN] VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES<br/>[FR] DÉRIVÉS VINYL-ARYLÉS UTILISÉES POUR TROUBLES INFLAMMATOIRES ET IMMUNITAIRES
  申请人：SYNTA PHARMACEUTICALS CORP

  公开号：WO2009017831A1

  公开（公告）日：2009-02-05

  The invention relates to compounds that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

  这项发明涉及可用作免疫抑制剂以及用于治疗和预防炎症症状、过敏性疾病和免疫性疾病的化合物。
• [EN] IMIDAZOLINONE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'IMIDAZOLINONE EN TANT QU'ANTAGONISTES DE RÉCEPTEURS CGRP
  申请人：MERCK SHARP & DOHME

  公开号：WO2010077752A1

  公开（公告）日：2010-07-08

  The present invention is directed to imidazolinone derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及嘧啶啉酮衍生物，其为CGRP受体拮抗剂，可用于治疗或预防涉及CGRP的疾病，如偏头痛。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗涉及CGRP的这类疾病中使用这些化合物和组合物。

表征谱图